サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1243267

ゴーシェ病治療薬の世界市場

Gaucher Disease Treatment
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ゴーシェ病治療薬の世界市場
出版日: 2023年03月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ゴーシェ病治療薬の世界市場は2030年に25億米ドルに達する

COVID-19後の変化したビジネス環境において、2022年に19億米ドルと推定されるゴーシェ病治療薬の世界市場は、2030年には25億米ドルに達すると予測され、2022年から2030年にかけてCAGR3.8%の成長率を記録すると予測されます。本レポートで分析したセグメントの一つである酵素補充療法は、CAGR3.4%を記録し、分析期間終了時には15億米ドルに達すると予測されます。パンデミック後の回復が進んでいることを考慮し、基質低減療法分野の成長は、今後8年間のCAGRが4.3%に修正されました。

米国市場は5億6,470万米ドル、中国はCAGR3.5%の成長を予測

米国のゴーシェ病治療薬市場は、2022年に5億6,470万米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが3.5％となり、2030年には4億4,850万米ドルの市場規模に達すると予測されます。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ3.5％と3.2％の成長が予測されています。欧州では、ドイツがCAGR3.8%で成長すると予測されています。

調査対象企業の例

  • Abbott
  • Actelion Pharmaceuticals Ltd.（Johnson & Johnson）
  • Anthera Pharmaceuticals, Inc.
  • Aptalis Pharma
  • BioMarin Pharmaceutical Inc.
  • Eli Lilly and Company
  • Enobia Pharma Inc.
  • Genzyme Corporation
  • GlaxoSmithKline（GSK）
  • JCR Pharmaceuticals Co Ltd
  • Lixte Biotechnology Holdings Inc
  • MedPro Rx
  • Merck Serono
  • Orphazyme ApS
  • Pfizer Inc.
  • Pharming Group NV
  • Shire Human Genetic Therapies, Inc.
  • Zymenex A/S

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP12147

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Gaucher Disease Treatment Market to Reach $2.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Gaucher Disease Treatment estimated at US$1.9 Billion in the year 2022, is projected to reach a revised size of US$2.5 Billion by 2030, growing at aCAGR of 3.8% over the period 2022-2030. Enzyme Replacement Therapy, one of the segments analyzed in the report, is projected to record 3.4% CAGR and reach US$1.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Substrate Reduction Therapy segment is readjusted to a revised 4.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $564.7 Million, While China is Forecast to Grow at 3.5% CAGR

The Gaucher Disease Treatment market in the U.S. is estimated at US$564.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$448.5 Million by the year 2030 trailing a CAGR of 3.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.5% and 3.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Select Competitors (Total 42 Featured) -

  • Abbott
  • Actelion Pharmaceuticals Ltd. (Johnson & Johnson)
  • Anthera Pharmaceuticals, Inc.
  • Aptalis Pharma
  • BioMarin Pharmaceutical Inc.
  • Eli Lilly and Company
  • Enobia Pharma Inc.
  • Genzyme Corporation
  • GlaxoSmithKline (GSK)
  • JCR Pharmaceuticals Co Ltd
  • Lixte Biotechnology Holdings Inc
  • MedPro Rx
  • Merck Serono
  • Orphazyme ApS
  • Pfizer Inc.
  • Pharming Group NV
  • Shire Human Genetic Therapies, Inc.
  • Zymenex A/S

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Gaucher Disease Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Gaucher Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Gaucher Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Substrate Reduction Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Substrate Reduction Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Substrate Reduction Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Non-neuronopathic Gaucher disease Clients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Non-neuronopathic Gaucher disease Clients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Non-neuronopathic Gaucher disease Clients by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Neuronopathic Gaucher disease Clients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Neuronopathic Gaucher disease Clients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Neuronopathic Gaucher disease Clients by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 16: World Gaucher Disease Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • JAPAN
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • CHINA
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: China 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: China 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • EUROPE
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Gaucher Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Gaucher Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • FRANCE
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: France 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: France 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • GERMANY
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Rest of Europe Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: Rest of Europe 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Gaucher Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Asia-Pacific 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Rest of World Historic Review for Gaucher Disease Treatment by Product Type - Enzyme Replacement Therapy and Substrate Reduction Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Rest of World 16-Year Perspective for Gaucher Disease Treatment by Product Type - Percentage Breakdown of Value Sales for Enzyme Replacement Therapy and Substrate Reduction Therapy for the Years 2014, 2023 & 2030
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Gaucher Disease Treatment by Disease - Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Gaucher Disease Treatment by Disease - Percentage Breakdown of Value Sales for Neuronopathic Gaucher disease Clients and Non-neuronopathic Gaucher disease Clients for the Years 2014, 2023 & 2030

IV. COMPETITION